Mesoblast Limited · ASX:MSB

Mesoblast — Shareholder Meeting (November 2026)

26 slides from Mesoblast's shareholder meeting presentation, Nov 12, 2026

  1. Slide 1: Annual General Meeting 2026

    Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases November 2026 ASX: MSB; Nasdaq: MESO Annual General Meeting 2026 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    2 This presentation includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ mat

  3. Slide 3: Corporate Vision

    To be the world’s leading and most innovative cellular medicines company To use our proprietary technologies to develop cellular medicines that are life-saving and that transform lives To be an organisation that displays efficiency and attracts highly motivated professionals working towards a common

  4. Slide 4: FY2026: Highlights for the Year and Delivery of Major Milestones

    4 FY2026: Highlights for the Year and Delivery of Major Milestones Successful first year for U.S. commercial launch of RYONCIL • FY2026 net revenue US$115M • Gross profit on total sales, excluding amortization expense, was US$110M Major milestones achieved ✓ Completed 350 patients treated in the Pha

  5. Slide 5: Our 'MOAT' – Our Market Leadership

    5 ✓ Global IP portfolio >1,100 patents and patent applications provide protection through >2044 ✓ Dominant IP underpins a scalable commercial business model for cell therapy products ✓ First mover advantage – RYONCIL is the first and only MSC approved by FDA ✓ Leverage FDA Guidance to obtain label e

  6. Slide 6: Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies

    6 Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies Ryoncil® Only FDA Approved MSC, Successful First US Launch Net revenue US$115M in FY2026 – first full year post launch Highly profitable single product on stand-alone basis Opportunities in adult aGvHD and other severe pediatric infl

  7. Slide 7: Operational Management and Board of Directors

    7 Operational Management • Search for US-based Chief Operating Officer (COO) to prepare for commercial manufacturing scale-up and potential commercial launch activities for rexlemestrocel-L • Dr. Greg George will be Interim COO, with extensive operational experience having founded and managed the la

  8. Slide 8: Mesoblast Worldwide Leader Allogeneic Mesenchymal Stromal Cell Portfolio

    8 Mesoblast Worldwide Leader Allogeneic Mesenchymal Stromal Cell Portfolio Assets Wholly Owned and Unencumbered in U.S. Markets SR-aGvHD = Steroid-Refractory Acute Graft versus Host Disease | HFrEF = Heart Failure with Reduced Ejection Fraction | CLBP = Chronic Low Back Pain | TAM = Total Addressabl

  9. Slide 9: RYONCIL: Steroid-Refractory Acute Graft Versus Host Disease

    9 RYONCIL® Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

  10. Slide 10: Adult SR-aGvHD Registration Trial and Label Extension Market

    10 • >2,000 adults annually in U.S. with SR-aGvHD of which ~50% have Grade III/IV disease • Registration trial: 180 Grade III/IV SR-aGvHD adults randomized 1:1 to ruxolitinib vs ruxolitinib + RYONCIL • Primary endpoint Day 28 overall response; secondary endpoint Day 180 overall survival • Targeting

  11. Slide 11: Rexlemestrocel-L Chronic Low Back Pain

    Rexlemestrocel-L Chronic Low Back Pain due to Degenerative Disc Disease (CLBP)

  12. Slide 12: Phase 3 Trial to Reduce Inflammation & Pain in Degenerative Disc Disease

    12 Phase 3 trial to Reduce Inflammation & Pain in Degenerative Disc Disease Targeted, minimally invasive delivery of rexlemestrocel-L to the degenerated disc Healthy disc • Hydrated nucleus • Intact annulus • Minimal nerve ingrowth Major Milestones to Commercial Launch 1 P3 trial 350 patients fully

  13. Slide 13: The Patient Treatment Journey

    13 The Patient Treatment Journey ~7M US patients have moderate / severe DDD within 5 years of diagnosis that is refractory to medical therapies including opioids Rexlemestrocel-L targeting moderate-to-severe CLBP NSAIDs Physical therapy Chiropractic treatments Acupuncture Anticonvulsants (e.g., gaba

  14. Slide 14: Pain Specialists are the Dominant Caregivers Seen by Patients with CLBP

    14 Pain Specialists are the Dominant Caregivers Seen by Patients with CLBP Primary Care Physician (50%) Other (Ortho-/Spine Surgeon, Neurosurgeon, Rehabilitative Medicine Specialist, and Interventional Radiologist) (10%) Patient Presents With Symptoms Pain Specialist or Anesthesiologist (40%) • Phys

  15. Slide 15: 85% of Pain Specialists Likely to Recommend Rexlemestrocel-L for CLBP

    15 Pain Specialist Neurosurgeon Ortho Surgeon 8% 8% 31% 8% 8% 31% 18% 31% 23% 69% 55% 15% 15% 8% 9% 31% 8% 18% 8% Likelihood of Recommendation Irrespective of Price: Pain and Function Data at 12 Months 50-74% likely25-49% likely1-24% likely0% likely 75-99% likely 100% likely Anesthesiology Guidehous

  16. Slide 16: Rexlemestrocel-L Heart Failure

    Rexlemestrocel-L Heart Failure

  17. Slide 17: Cardiopulmonary Indications Leveraging Rexlemestrocel-L Mechanism

    17 Cardiopulmonary Indications Leveraging Rexlemestrocel-L Mechanism LVAD BLA approval for rexlemestrocel-L can open label extension potential in two additional blockbuster indications with same mechanism of action Intra-Myocardial Rexlemestrocel-L Reduces Inflammation And Reverses Endothelial Dysfu

  18. Slide 18: FDA Filing for Rexlemestrocel-L in Patients with LVADs

    18 • File with FDA for full approval for rexlemestrocel-L in patients with LVADs • Major GI Bleeding is an FDA-acknowledged indication with rexlemestrocel-L having received Orphan Drug designation • FDA has confirmed at a recent meeting that the BLA filing may proceed for patients with life- threate

  19. Slide 19: Group 2 Pulmonary Hypertension (Due to LV Dysfunction)

    19 Group 2 Pulmonary Hypertension (Due to LV Dysfunction) Left-heart disease raises pulmonary pressure and right ventricular load Left-heart disease Pulmonary venous hypertension Right ventricular strain LV or valve disease raises left atrial pressure Pressure backs up into lung veins and capillarie

  20. Slide 20: Rexlemestrocel-L Improved Survival in HFrEF with Group 2 PH in DREAM-HF

    20 Rexlemestrocel-L Improved Survival in HFrEF with Group 2 Pulmonary Hypertension in DREAM-HF Trial • In the DREAM-HF population with HFrEF, 219 patients had established Group 2 Pulmonary Hypertension, defined by pulmonary artery systolic pressure (PASP) >35 mmHg, • Across all 219 patients, a singl

  21. Slide 21: Group 2 PH: A Large Unmet Need with No Approved Drugs

    21 Group 2 PH: A Large Unmet Need with No Approved Drugs Left heart disease is the most common cause of pulmonary hypertension, creating a substantial addressable population 2 GROUP 2 PH - CLINICAL CONTEXT Most common PH group Approximately 40% of left-sided heart failure No approved drug therapy To

  22. Slide 22: Next Generation Technologies CAR-MSC

    22 Next Generation Technologies CAR-MSC mesoblast 22

  23. Slide 23: The Future: Genetically-Modified CAR-MSC Platform

    23 The Future: Genetically-Modified CAR-MSC Platform • Leverage technology behind CAR-T therapies without issues re: (i) safety and (ii) manufacturing • Broad range of potential target antigens/intracellular pathway choices • Enhanced targeting results in increased potency • Lead products target Lup

  24. Slide 24: In Summary

    24 In Summary

  25. Slide 25: Summary of Major Milestones

    25 Summary of Major Milestones Commercial growth and label expansion for RYONCIL, alongside advancement of rexlemestrocel-L blockbuster programs 1 COMMERCIAL + LABEL EXPANSION RYONCIL® (remestemcel-L-rknd) GROW Strongly expand the revenue base and increase penetration of pediatric SR-aGvHD EXPAND Co

  26. Slide 26: Thank You

    “Jmesoblast Thank You

Mesoblast — Shareholder Meeting (November 2026) on 6ix